Cancer Immunotherapy Market Report 2025

This Cancer Immunotherapy market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cancer immunotherapy market size has grown rapidly in recent years. It will grow from $110.91 billion in 2024 to $125.68 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising prevalence of cancer, increased adoption of immunotherapy over traditional therapy, growing R&D activities for the development of targeted diseases, increased effectivity and accuracy of newer therapies, growing recognition of the limitations of traditional cancer treatments.

The cancer immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $194.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing approval of novel immunotherapies for cancer treatment, growing demand for personalized medicine, rising cases of people being detected with cancer, increasing investment in clinical trials to introduce cutting-edge treatments, growing awareness about cancer immunotherapy. Major trends in the forecast period include emergence of adoptive cell therapies, including car-t cells, exploration of oncolytic viruses in cancer immunotherapy, development of personalized cancer vaccines, utilization of artificial intelligence in immunotherapy research, increasing emphasis on real-world evidence and patient outcomes in treatment decisions.

The rise in cancer incidence is expected to propel the cancer immunotherapy market. The factors contributing to the growth in cancer cases across the globe include tobacco, alcohol, obesity, a sedentary lifestyle, and environmental factors. This growth in cancer cases is expected to boost demand for cancer immunotherapies, as patients are increasingly investing in medical treatments with greater recovery and minimal pain. For instance, in October 2023, according to the European Union Science Hub, a Belgium-based European Commission's Joint Research Centre, new cancer cases increased by 2.3% during the preceding two years, reaching 2. 74 million in 2022. Similarly, cancer fatalities increased by 2.4% during the preceding two years. Therefore, the increase in cancer incidence is expected to boost demand for cancer immunotherapy during forecast period.

The increasing emergence of biosimilars is expected to propel the growth of the cancer immunotherapy market in the coming years. Biosimilars are biological medical products that are very similar to an existing authorized biological drug (the reference product) and are designed to have no clinically significant variations in terms of safety, effectiveness, and quality from the reference product. Biosimilars have great potential in cancer immunotherapy because they increase treatment accessibility, stimulate competition, lower prices, and provide more sustainable and diverse therapeutic alternatives for cancer patients. For instance, in 2022, according to Amgen Inc., a US-based biopharmaceutical company, the FDA reported 96 proposed biosimilar drugs registered in the FDA's Biosimilar Development Program as of Q2 2022, a nearly 70% increase. Therefore, the increasing emergence of biosimilars is driving the cancer immunotherapy market.

Advanced technologies used in cancer immunotherapy are a key trend gaining popularity in the cancer immunotherapy market. There has been a surge of new technologies and various therapies to help the immune system identify and attack tumors using different therapies and technologies such as immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy. These technologies can make a significant difference in cancer treatment and cure. For instance, in October 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, announced that it had received approval for its Capivasertib in combination with Faslodex. This drug is a cancer immunotherapeutic developed for the treatment of breast cancer and is effective in following recurrence or advancement on or after endocrine therapy in locally progressed or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2).

Major companies operating in the cancer immunotherapy market are focusing on developing innovative products, such as Imjudo in combination with Imfinzi, to better meet the needs of their existing consumers. Imjudo, a combination of Imfinzi (durvalumab) and tremelimumab, is a possible dual immune checkpoint inhibitor in cancer immunotherapy. For instance, in October 2022, AstraZeneca Plc, a UK-based biotechnology and pharmaceutical company, announced the approval of Imjudo and Imfinzi for the treatment of unresectable hepatocellular carcinoma (HCC). The STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) refers to the innovative dose and schedule of the combination, which involves a single dose of the anti-CTLA-4 antibody Imjudo 300mg combined with the anti-PD-L1 antibody Imfinzi 1500mg followed by Imfinzi every four weeks.

In July 2024, Boehringer Ingelheim, a pharmaceutical company based in Germany, acquired Nerio Therapeutics for $1.3 billion. This acquisition will greatly strengthen Boehringer Ingelheim's immuno-oncology portfolio by incorporating Nerio's innovative preclinical program centered on immune checkpoint inhibitors. Nerio Therapeutics, a biotech company located in the US, specializes in drug discovery and development, particularly focusing on phosphatases, which are a challenging but highly promising class of therapeutic protein targets.

Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

Cancer immunotherapy refers to a type of cancer therapy that strengthens your body's defenses against the disease. Your body's immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.

The main types of products of cancer immunotherapy are monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy. Monoclonal antibodies are man-made proteins that function in the immune system such as human antibodies. Cancer immunotherapy is used to treat lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and multiple myeloma. These are used in hospitals, cancer research centers, and clinics.

The cancer immunotheraphy market research report is one of a series of new reports that provides cancer immunotheraphy market statistics, including cancer immunotheraphy industry global market size, regional shares, competitors with a cancer immunotheraphy market share, detailed cancer immunotheraphy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotheraphy industry. This cancer immunotheraphy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The cancer immunotherapy market includes revenues earned by entities by helping the immune system fight cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.